Equities research analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.12). Caladrius Biosciences also reported earnings per share of ($0.10) […]
Caladrius Biosciences (NASDAQ:CLBS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.65% from the stock’s […]
StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBS – Get Rating) in a report released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright cut their price target on Caladrius Biosciences from $8.00 to $6.00 and set a buy rating on the stock in a research note […]
Analysts expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) will announce ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.13). Caladrius Biosciences posted earnings per share of ($0.28) […]